

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1614
BRINKMANN, VOLKER ET AL. EXAMINER: MARSCHEL, ARDIN H
INTERNATIONAL APPLICATION NO: PCT/EP2004/014436
FILED: DECEMBER 17, 2004
U.S. APPLICATION NO: 10/583106
35 USC §371 DATE: JULY 19, 2006
FOR: USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR
AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE
DISEASES

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed June 18, 2009.
- ☒ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

- ☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9273


Cozette McAvoy
Attorney for Applicant
Reg. No. 60,457

Date: *3rd November 2009*